Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma-MedSci.cn

Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma

Shi, YK; Zhang, QY; Han, XH; Qin, Y; Ke, XY; Su, H; Liu, L; Fu, JX; Jin, J; Feng, JF; Hong, XN; Zhang, XH; Wu, DP; Jiang, B; Dong, XD

Shi, YK (corresponding author), Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing 100021, Peoples R China.; Shi, YK (corresponding author), Chinese Acad Med Sci, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.

Abstract

Objective: This study aimed to compare the pharmacokinetic, pharmacodynamic and safety profiles of HLX01 (a rituximab biosimilar) and reference rituxi......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma

科室

工具

服务